Published in Bioinformatics on January 19, 2007
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet (2010) 2.39
PASSion: a pattern growth algorithm-based pipeline for splice junction detection in paired-end RNA-Seq data. Bioinformatics (2012) 1.95
Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet (2014) 1.60
Systematic discovery of complex insertions and deletions in human cancers. Nat Med (2015) 0.83
Breaking the computational barrier: a divide-conquer and aggregate based approach for Alu insertion site characterisation. Int J Comput Biol Drug Des (2009) 0.82
Label noise in subtype discrimination of class C G protein-coupled receptors: A systematic approach to the analysis of classification errors. BMC Bioinformatics (2015) 0.76
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem (2010) 1.88
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem (2008) 1.87
Multi-RELIEF: a method to recognize specificity determining residues from multiple sequence alignments using a Machine-Learning approach for feature weighting. Bioinformatics (2007) 1.51
Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. J Biol Chem (2010) 1.37
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Internalization and desensitization of adenosine receptors. Purinergic Signal (2007) 1.21
A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinformatics (2010) 1.11
Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol (2004) 1.09
Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus. Planta Med (2009) 1.08
A two-entropies analysis to identify functional positions in the transmembrane region of class A G protein-coupled receptors. Proteins (2006) 1.07
Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev (2005) 1.07
G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands. Med Res Rev (2008) 1.03
Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem (2005) 1.02
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem (2004) 1.02
Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action. J Med Chem (2005) 1.02
Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data. PLoS Comput Biol (2013) 1.01
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol (2011) 0.99
Nicotinic acid receptor subtypes and their ligands. Med Res Rev (2007) 0.98
Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands. Mol Cell Endocrinol (2012) 0.97
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol (2008) 0.97
How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. J Chem Inf Model (2013) 0.97
Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol (2013) 0.96
The role of a sodium ion binding site in the allosteric modulation of the A(2A) adenosine G protein-coupled receptor. Structure (2013) 0.95
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J Med Chem (2006) 0.94
Substructure mining using elaborate chemical representation. J Chem Inf Model (2006) 0.92
The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. Curr Opin Struct Biol (2010) 0.92
GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J (2010) 0.91
Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen (2012) 0.90
Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. J Med Chem (2012) 0.90
Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem (2010) 0.90
[3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor. Mol Pharmacol (2007) 0.89
Benchmarking of protein descriptor sets in proteochemometric modeling (part 2): modeling performance of 13 amino acid descriptor sets. J Cheminform (2013) 0.89
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. PLoS One (2011) 0.88
Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor. Br J Pharmacol (2002) 0.88
Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor. J Med Chem (2009) 0.87
Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists. J Med Chem (2013) 0.87
Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther (2011) 0.87
A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem (2009) 0.86
Structure-affinity relationships of adenosine A2B receptor ligands. Med Res Rev (2006) 0.86
Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. J Med Chem (2009) 0.85
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. Eur J Pharm Sci (2003) 0.84
Allosteric modulation of purine and pyrimidine receptors. Adv Pharmacol (2011) 0.84
Substructure-based virtual screening for adenosine A2A receptor ligands. ChemMedChem (2011) 0.84
Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. ACS Chem Biol (2012) 0.84
Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorg Med Chem (2005) 0.84
Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets. J Cheminform (2013) 0.84
Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases. ChemMedChem (2010) 0.83
Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J Med Chem (2014) 0.83
2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem (2006) 0.82
Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2. Mol Pharmacol (2013) 0.82
Caffeine increases light responsiveness of the mouse circadian pacemaker. Eur J Neurosci (2014) 0.82
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem (2005) 0.82
Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol (2008) 0.81
Mining protein dynamics from sets of crystal structures using "consensus structures". Protein Sci (2010) 0.81
Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor. ChemMedChem (2014) 0.79
A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. J Med Chem (2012) 0.79
Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signal (2011) 0.79
Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues. ChemMedChem (2009) 0.79
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. Eur J Pharm Sci (2005) 0.78
The structure of the adenosine receptors: implications for drug discovery. Adv Pharmacol (2011) 0.78
Techniques: how to boost GPCR mutagenesis studies using yeast. Trends Pharmacol Sci (2005) 0.78
Adenosine A₂B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2012) 0.78
Characterization of [3H]LUF5834: A novel non-ribose high-affinity agonist radioligand for the adenosine A1 receptor. Biochem Pharmacol (2010) 0.78
2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem (2007) 0.78
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. Eur J Pharmacol (2005) 0.77
Partial adenosine A(1) receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice. Eur J Pharmacol (2003) 0.77
Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues. J Med Chem (2013) 0.77
Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice. Br J Pharmacol (2012) 0.76
Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships. Eur J Pharm Sci (2003) 0.75
Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding. ChemMedChem (2008) 0.75
Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A). J Med Chem (2012) 0.75
The mouse brain adenosine A1 receptor: functional expression and pharmacology. Eur J Pharmacol (2004) 0.75
Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat. Eur J Pharmacol (2004) 0.75
Multi-objective evolutionary design of adenosine receptor ligands. J Chem Inf Model (2012) 0.75
Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem (2007) 0.75
Non-xanthine antagonists for the adenosine A1 receptor. Chem Biodivers (2004) 0.75